Abstract:A number of conditions and factors can cause the transformation of normal cells in the body into malignant tissue by changing the normal functions of a wide range of regulatory, apoptotic, and signal transduction pathways. Despite the current deficiency in fully understanding the mechanism of cancer action accurately and clearly, numerous genes and proteins that are causally involved in the initiation, progression, and metastasis of cancer have been identified. But due to the lack of space and the abundance of details on this complex topic, we have emphasized here more recent advances in our understanding of the principles implied tumor cell transformation, development, invasion, angiogenesis, and metastasis. Inhibition of angiogenesis is a significant strategy for the treatment of various solid tumors, that essentially depend on cutting or at least limiting the supply of blood to micro-regions of tumors, leading to pan-hypoxia and pan-necrosis inside solid tumor tissues. Researchers have continued to enhance the efficiency of anti-angiogenic drugs over the past two decades, to identify their potential in the drug interaction, and to discover reasonable interpretations for possible resistance to treatment. In this review, we have discussed an overview of cancer history and recent methods use in cancer therapy, focusing on anti-angiogenic inhibitors targeting angiogenesis formation. Further, this review has explained the molecular mechanism of action of these anti-angiogenic inhibitors in various tumor types and their limitations use. In addition, we described the synergistic mechanisms of immunotherapy and anti-angiogenic therapy and summarizes current clinical trials of these combinations. Many phase III trials found that combining immunotherapy and anti-angiogenic therapy improved survival. Therefore, targeting the source supply of cancer cells to grow and spread with new anti-angiogenic agents in combination with different conventional therapy is a novel method to reduce cancer progression. The aim of this paper is to overview the varying concepts of cancer focusing on mechanisms involved in tumor angiogenesis and provide an overview of the recent trends in anti-angiogenic strategies for cancer therapy.

Current status of cancer starvation therapy

Advances in nanomedicine for cancer starvation therapy

Augmenting Tumor‐Starvation Therapy by Cancer Cell Autophagy Inhibition

When Starvation Therapy Meets Chemodynamic Therapy

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

A “Valve‐Closing” Starvation Strategy for Amplification of Tumor‐Specific Chemotherapy

Focused starvation of tumor cells using glucose oxidase: A comprehensive review

Enhanced Cancer Starvation Therapy Based on Glucose Oxidase/3-Methyladenine-Loaded Dendritic Mesoporous OrganoSilicon Nanoparticles

Enhanced Cancer Starvation Therapy via Autophagy Inhibition With a Functional Dendritic Mesoporous Organosilicon Nanoagent

Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy

Targeting the Proline–Glutamine–Asparagine–Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy

Biomimetic Synthesis of a Novel O2-regeneration Nanosystem for Enhanced Starvation/chemo-Therapy.

Nutritional Therapy Strategies Targeting Tumor Energy Metabolism

Advanced Cancer Starvation Therapy by Simultaneous Deprivation of Lactate and Glucose Using a MOF Nanoplatform

Anti-angiogenic Therapy for Tumor: Tumor Angiogenesis, Vasculogenic Mimicry and Vascular Normalization

Biomimetic synthesis of a novel O 2 -regeneration nanosystem for enhanced starvation/chemo-therapy

Targeting Nutrient Dependency in Cancer Treatment

An Overview of Cancer Biology, Pathophysiological Development and It's Treatment Modalities: Current Challenges of Cancer anti-Angiogenic Therapy

Hypoxia-responsive nanoparticles for tumor-specific starvation therapy via a two-pronged approach

Nano-Platelets as an Oxygen Regulator for Augmenting Starvation Therapy Against Hypoxic Tumor

Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer